Elanco Secures USDA Approval For Befrena, Expands Dermatology Portfolio
I'm PortAI, I can summarize articles.
Elanco Animal Health Inc. has received USDA approval for Befrena, a new anti-IL31 monoclonal antibody injection for treating canine allergic and atopic dermatitis. Recommended every 6 to 8 weeks, Befrena offers a longer treatment interval than its competitor, lokivetmab. The product is set to launch in the first half of 2026, marking Elanco's second dermatology product approval in 18 months. Elanco's stock closed at $22.63, down 0.57%, and further declined to $22.16 in after-hours trading.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments